BioNanomatrix LLC
This article was originally published in Start Up
Executive Summary
BioNanomatrix envisions multiple potential applications for its NANOANALYZER benchtop-sized molecular optical imager capable of scanning single molecules. DNA sequencing is one--the company thinks its technology's ability to deliver single molecule sensitivity in a highly parallel format with minimal processing will provide a fast, low cost solution.
You may also be interested in...
Next-generation Sequencing: Slowly Moving towards the $1,000 Genome
Even if most attempts to read DNA strands in real time appear stalled and the goal of true single-molecule sequencing has, with the notable exception of Helicos, for the most part given way (at least for the time being) in favor of cluster-based approaches with lower data densities, there's still plenty of opportunity for start-ups to advance the field of next-generation sequencing: with microfluidics, nanotechnology, and biochemistries to better enable direct DNA observation and analysis.
Biodesy LLC
Second-harmonic generation is an optical phenomenon that occurs when a nonlinear surface combines photons of light to produce photons with twice the frequency and half the wavelength of the original photons. Biodesy is harnessing its power to measure protein conformation for drug discovery.
Jenken Biosciences Inc.
At present, there are no approved small molecule anti-inflammatory drugs for treating hepatitis C. Indeed, most drug R&D activity for hepatitis centers on new or improved anti-viral therapy rather than complications of the infection, e.g., the chronic inflammation that occurs in 80% of hepatitis cases. Jenken Biosciences hopes to change that. Jenken is repurposing two different, chemically similar, marketed compounds for new indications associated with chronic organ inflammation.